<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223843</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0095</org_study_id>
    <secondary_id>2019-001719-21</secondary_id>
    <nct_id>NCT04223843</nct_id>
  </id_info>
  <brief_title>A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Compare the Efficacy of Inhaled Tiotropium + Olodaterol, Fixed Dose Combination (5 mcg/5mcg) vs. Placebo Delivered by Respimat Inhaler in Patients With Moderate to Severe COPD, Stratified by Peak Inspiratory Flow Rate [TRONARTO].</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function
      in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal
      and sub-optimal Peak Inspiratory Flow Rate (PIFR). Disease severity (moderate to severe) is
      based on the Global Initiative for Chronic Lung Disease (GOLD) guidelines (GOLD 2 - 3)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Forced Expiratory Volume in one second (FEV1) area under the curve from 0 to 3 hours (AUC0-3h) after 4 weeks of treatment.</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough Forced Expiratory Volume in one second (FEV1).</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo via Respimat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium + olodaterol</intervention_name>
    <description>Oral Inhalation</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Inhalation</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent in accordance with International Council on
             Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to
             admission to the trial.

          -  Male or female patients, 40 years of age or older.

          -  All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria: patients with a post-bronchodilator Forced
             Expiratory Volume in one second (FEV1) &gt;30% and &lt;80% of predicted normal (European
             Coal and Steel Community (ECSC), [R94-1408]); and a postbronchodilator FEV1/
             Functional Residual Capacity (FVC) &lt;70%, at the screening visit.

          -  Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years

          -  Patients should meet the peak inspiratory flow rate criteria (optimal or sub-optimal)
             at the time of randomization depending on which strata is available for inclusion in
             the study.

          -  Women of childbearing potential must be ready and able to use highly effective methods
             of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per
             year when used consistently and correctly. A list of contraception methods meeting
             these criteria is provided in the patient information.

          -  Patients are expected to be able to perform, according to investigator's judgment, all
             trial related procedures including:

               -  Technically acceptable pulmonary function tests (spirometry)

               -  Use of In-Check DIAL G16 device to measure peak inspiratory flow rate.

               -  Inhale medication in a competent manner (in the opinion of the investigator) from
                  the Respimat® device

               -  Perform technically acceptable body plethysmography measurements. This is
                  applicable only to patients who will consent to the optional trial procedure at
                  the selected sites.

        Exclusion Criteria:

          -  Patients with a significant disease other than chronic obstructive pulmonary disease;
             a significant disease defined as a disease which, in the opinion of the investigator,
             and referring to the warnings to be observed as quoted in the locally applicable SmPC
             or prescribing information, could (i) put the patient at risk because of participation
             in the trial, (ii) influence the results of the trial, or (iii) cause concern
             regarding the patient's ability to participate in the trial.

          -  Patients who have had a chronic obstructive pulmonary disease exacerbation that
             required treatment with antibiotics, systemic steroids (oral or intravenous) or
             hospitalization in the 6 weeks prior to screening visit or during the screening
             period.

          -  Patients who experienced two or more moderate chronic obstructive pulmonary disease
             exacerbations (exacerbation that required treatment with antibiotics and/or oral
             corticosteroids), or one or more exacerbation leading to hospitalization within a year
             prior to visit 1.

          -  Patients with a history of asthma. For patients with allergic rhinitis or atopy,
             source documentation is required to verify that the patient does not have asthma.

          -  Patients taking inhaled corticosteroids (including combinations, e.g. inhaled
             corticosteroids / Long-Acting β2-agonist) in the 6 months prior to screening visit.

          -  Patients being treated with oral corticosteroid medication due to reasons other than
             chronic obstructive pulmonary disease exacerbation within 6 weeks prior to the
             screening visit.

          -  Patients who have completed a pulmonary rehabilitation program in the 6 weeks prior to
             screening visit or patients who are currently in a pulmonary rehabilitation program.

          -  Further criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SEC Lung</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research, LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Westerman</last_name>
      <phone>+001 (205) 387-7555</phone>
      <email>drwesterman@sleepfirst.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Specialists Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Weinstein</last_name>
      <phone>+001 (714) 848-8585</phone>
      <email>sfw@ocallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waterbury Pulmonary Associates LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Meris Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragos Zanchi</last_name>
      <phone>+001 (813) 413-7218</phone>
      <email>dragoszanchi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Dunn</last_name>
      <phone>+001 (727) 466-0078</phone>
      <email>ldunn@crwf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PDS Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Specialists LLC</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fortune Alabi</last_name>
      <phone>+001 (407) 507-2615</phone>
      <email>falabi@floridalungdoctors.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lon Lynn</last_name>
      <phone>+001 (813) 870-1292</phone>
      <email>llynn@crwf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mascolo</last_name>
      <phone>+001 (912) 303-5983</phone>
      <email>mmascolo@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trials, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Walker</last_name>
      <phone>+001 (504) 897-5211</phone>
      <email>Gwalkermd@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infinity Medical Research</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Mello</last_name>
      <phone>+001 (508) 998-3041</phone>
      <email>cjmello@infinitymedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Rsrch Inst of SE MI</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Ferguson</last_name>
      <phone>+001 (248) 478-6806</phone>
      <email>garytferguson@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center and Sleep Institute</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Grullon</last_name>
      <phone>+001 (952) 852-5274</phone>
      <email>Dr.Grullon@MnLungResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Wright</last_name>
      <phone>+001 (952) 852-5268</phone>
      <email>Dr.Wright@MnLungResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Regional Hospital</name>
      <address>
        <city>Claremont</city>
        <state>New Hampshire</state>
        <zip>03743</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHEAR Center LLC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Donath</last_name>
      <phone>+001 (917) 584-3332</phone>
      <email>elie@chearcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kernodle Clinic West</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig LaForce</last_name>
      <phone>+001 (919) 881-0309</phone>
      <email>claforce@nccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Sigal</last_name>
      <phone>+001 (336) 659-8414</phone>
      <email>bsigal@salemchest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Rsrch Ctr</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bernstein</last_name>
      <phone>+001 (513) 354-1746</phone>
      <email>jbernstein@bernsteincrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung and Critical Care</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kaelin</last_name>
      <phone>+001 (843) 256-3538</phone>
      <email>tkaelin@lowcountrylung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Research</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Patel</last_name>
      <phone>+001 (864) 905-7900</phone>
      <email>NPatel@CarolinaMedicalResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research -Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Erb</last_name>
      <phone>+001 (864) 488-1283</phone>
      <email>derb.md@vitalinkresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitalink Research - Spartansburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Feldman</last_name>
      <phone>+001 (864) 515-0092</phone>
      <email>Gfeldman.md@vitalinkresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Andrews</last_name>
      <phone>+001 (210) 692-7157</phone>
      <email>dr.andrews@dxrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin GbR</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Schenkenberger</last_name>
      <phone>+49 (30) 20859400</phone>
      <email>schenkenberger@klinische-forschung-berlin.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Oliver Kornmann</last_name>
      <phone>+49 (69) 695972580</phone>
      <email>kornmann@ikf-pneumologie.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Watz</last_name>
      <phone>+49 (4102) 8881122</phone>
      <email>h.watz@pulmoresearch.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamburger Institut für Therapieforschung GmbH (HIT)</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margret Jandl</last_name>
      <phone>+49 (40) 3808997722</phone>
      <email>jandl@hit-forschung.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung Lübeck GmbH</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ludwig-Sengpiel</last_name>
      <phone>+49 (451) 7078300</phone>
      <email>a.ludwig@klb-healthresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

